Engineered extracellular vesicles: A new approach for targeted therapy of tumors and overcoming drug resistance

Cancer Commun (Lond). 2024 Feb;44(2):205-225. doi: 10.1002/cac2.12518. Epub 2023 Dec 28.

Abstract

Targeted delivery of anti-tumor drugs and overcoming drug resistance in malignant tumor cells remain significant clinical challenges. However, there are only few effective methods to address these issues. Extracellular vesicles (EVs), actively secreted by cells, play a crucial role in intercellular information transmission and cargo transportation. Recent studies have demonstrated that engineered EVs can serve as drug delivery carriers and showed promising application prospects. Nevertheless, there is an urgent need for further improvements in the isolation and purification of EVs, surface modification techniques, drug assembly processes, and precise recognition of tumor cells for targeted drug delivery purposes. In this review, we summarize the applications of engineered EVs in cancer treatment and overcoming drug resistance, and current challenges associated with engineered EVs are also discussed. This review aims to provide new insights and potential directions for utilizing engineered EVs as targeted delivery systems for anti-tumor drugs and overcoming drug resistance in the near future.

Keywords: drug delivery; drug resistance; extracellular vesicles; nanoparticles.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Drug Resistance
  • Extracellular Vesicles*
  • Humans
  • Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents